Akeso, Inc. Completes Patient Enrollment in Global Phase III Trial Evaluating Ivonescimab for First-Line Treatment of Squamous NSCLC

 Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  is excited to announce the completion of patient enrollment in the global Phase III clini...

February 06, 2025 | Thursday | News
AstraZeneca’s Imfinzi® Receives Positive CHMP Recommendation for Limited-Stage Small Cell Lung Cancer Treatment in the EU

AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults ...

February 05, 2025 | Wednesday | News
Halozyme's Subcutaneous RYBREVANT® Formulation Receives Positive CHMP Opinion for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...

February 04, 2025 | Tuesday | News
HR+/HER2- Breast Cancer Market Sees Growth and Innovation in Treatment Options

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progeste...

February 04, 2025 | Tuesday | News
EMA's CHMP Recommends Opdivo® + Yervoy® for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

 Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

February 03, 2025 | Monday | News
Roche's PATHWAY® Anti-HER2 Test Gains FDA Approval to Identify HER2-Ultralow Metastatic Breast Cancer Patients for ENHERTU® Treatment

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced  that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® ant...

February 03, 2025 | Monday | News
Kazia Therapeutics Launches Groundbreaking Clinical Trial Combining Paxalisib and Immunotherapy for Advanced Breast Cancer

Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch...

January 31, 2025 | Friday | News
Amgen Announces European Commission Approval of BLINCYTO® for Frontline Treatment of B-ALL

Amgen (NASDAQ:AMGN) announced that the European Commission (EC) has approved BLINCYTO® (blinatumomab) monotherapy as part of consolidation therapy...

January 31, 2025 | Friday | News
Zerion Pharma Partners with Aché to Enhance Global Oncology and Neuroscience Drugs Using Dispersome® Technology

Zerion Pharma A/S  announces a partnership with Aché Laboratorios Farmacêuticos S.A. (“ACHÉ”), a major Brazilian p...

January 30, 2025 | Thursday | News
Datar Cancer Genetics Launches AI-Powered Video Reporting Service for Chemosensitivity Testing

Datar Cancer Genetics (DCG) has launched a revolutionary video reporting service for in vitro chemosensitivity testing, powered by AI-based technology. Thi...

January 29, 2025 | Wednesday | News
Roche Announces Positive Overall Survival Results for Itovebi™ in Advanced Breast Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating...

January 29, 2025 | Wednesday | News
Pfizer to Present Groundbreaking Genitourinary Cancer Research at ASCO GU 2025

Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitour...

January 29, 2025 | Wednesday | News
European Commission Approves LAZCLUZE® (lazertinib) and RYBREVANT® (amivantamab) for First-Line Treatment of EGFR-Mutant Advanced NSCLC

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has granted marketing authorization (MA) to LA...

January 28, 2025 | Tuesday | News
AstraZeneca and Daiichi Sankyo's Enhertu Gains FDA Approval for HER2-Low and HER2-Ultralow Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unre...

January 28, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close